Proceedings of the National Academy of Sciences · 2022 · 116 citations · 32 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyRadiobiologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsRadiation ImmunobiologyRadiation TherapyRadiation-induced Cell DeathCd8 T Cell ActivationCyclic Gmp-amp Synthase SignalingGasdermin D-mediated PyroptosisImmune Modulation By RadiationProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 InhibitionRadiation Effects On The Gastrointestinal TractTumor Immunogenicity
DNA-damaging treatments such as radiotherapy (RT) have become promising to improve the efficacy of immune checkpoint inhibitors by enhancing tumor immunogenicity. However, accompanying treatment-related detrimental events in normal tissues have posed a major obstacle to radioimmunotherapy and present new challenges to the dose delivery mode of clinical RT. In the present study, ultrahigh dose rate FLASH X-ray irradiation was applied to counteract the intestinal toxicity in the radioimmunotherapy. In the context of programmed cell death ligand-1 (PD-L1) blockade, FLASH X-ray minimized mouse enteritis by alleviating CD8 + T cell-mediated deleterious immune response compared with conventional dose rate (CONV) irradiation. Mechanistically, FLASH irradiation was less efficient than CONV X-ray in eliciting cytoplasmic double-stranded DNA (dsDNA) and in activating cyclic GMP-AMP synthase (cGAS) in the intestinal crypts, resulting in the suppression of the cascade feedback consisting of CD8 + T cell chemotaxis and gasdermin E-mediated intestinal pyroptosis in the case of PD-L1 blocking. Meanwhile, FLASH X-ray was as competent as CONV RT in boosting the antitumor immune response initiated by cGAS activation and achieved equal tumor control in metastasis burdens when combined with anti–PD-L1 administration. Together, the present study revealed an encouraging protective effect of FLASH X-ray upon the normal tissue without compromising the systemic antitumor response when combined with immunological checkpoint inhibitors, providing the rationale for testing this combination as a clinical application in radioimmunotherapy.
32
Hallmarks of Cancer: New Dimensions
Cancer Discovery · 2022 · 9.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Jianjin Shi, Yue Zhao, Kun Wang et al. · Nature · 2015 · 6.5K citations
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Yupeng Wang, Wenqing Gao, Xuyan Shi et al. · Nature · 2017 · 3.2K citations
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins, Sam J. Wilson, Maryline Panis et al. · Nature · 2011 · 2.5K citations